MIDRIX is a proprietary dendritic cell immunotherapy platform developed at UGent (Prof. Dr. K. Vermaelen group, in collaboration with Prof. Dr. Bart Vandekerckhove), and is now in early clinical testing in lung cancer (MIDRIX4-LUNG). A spin-off track has been defined to allow further technological and clinical development of this cutting-edge therapeutic in oncology. The general aim of this project is value creation based on several distinct, yet inter-connected areas in order to attract venture capital and spin-off the company (SparXells™), focusing on strategic IP, scale-up of the MIDRIX production platform and the preparation of a follow-on clinical study. The final deliverable is a robust business plan that defines the development strategy of MIDRIX-based therapeutics with expected returns for investors/shareholders, including UGent.